Gene: CACNB2

783
CACNLB2|CAVB2|MYSB
calcium voltage-gated channel auxiliary subunit beta 2
protein-coding
10p12.33-p12.31
Ensembl:ENSG00000165995 MIM:600003 Vega:OTTHUMG00000017764 UniprotKB:Q08289
NG_016195.1
SNP Mapped
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.891e-1 (AD)  3.819e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12240995chr10:18348303 (GRCh38.p7)A>Cnicotine dependenceSNV(Single Nucleotide Variation)
rs1277769chr10:18210865 (GRCh38.p7)C>Anicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg12289251chr10:18689471CACNB24.200e-13Smoking27651444
cg24128066chr10:18689503CACNB21.200e-10Smoking27651444
cg00177243chr10:18434068CACNB27.800e-10Smoking27651444
cg22858500chr10:18629006CACNB22.200e-9Smoking27651444
cg14357089chr10:18550033CACNB29.100e-8Smoking27651444
cg00476617chr10:18492374CACNB29.700e-8Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NCEH10.954
FBXO340.953
GABRB30.951
DAPK10.945
NOL40.944
CNKSR20.943
CDK200.942
AMIGO10.941
RBFOX20.94
GRIA20.939

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RAI14-0.543
SGMS2-0.517
MYL3-0.511
TFPI2-0.506
FZD10-0.502
HEY2-0.501
CTNNA3-0.5
CSAG1-0.497
TGFB3-0.487
SH2D1A-0.477

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB11093Calcium CitrateSmall Molecule813-94-5ApprovedTransporter
DB11348Calcium PhosphateSmall Molecule10103-46-5ApprovedTransporter
DB00270IsradipineSmall Molecule75695-93-1Approved|InvestigationalTarget
DB00381AmlodipineSmall Molecule88150-42-9ApprovedTarget
DB00393NimodipineSmall Molecule66085-59-4Approved|InvestigationalTarget
DB00401NisoldipineSmall Molecule63675-72-9ApprovedTarget
DB00622NicardipineSmall Molecule55985-32-5Approved|InvestigationalTarget
DB00653Magnesium sulfateSmall Molecule7487-88-9Approved|InvestigationalTarget
DB00661VerapamilSmall Molecule52-53-9ApprovedTarget
DB01023FelodipineSmall Molecule72509-76-3Approved|InvestigationalTarget
DB01054NitrendipineSmall Molecule39562-70-4Approved|InvestigationalTarget
DB01115NifedipineSmall Molecule21829-25-4ApprovedTarget
DB01388MibefradilSmall Molecule116644-53-2Investigational|WithdrawnTarget
DB04855DronedaroneSmall Molecule141626-36-0ApprovedTarget
DB06712NilvadipineSmall Molecule75530-68-6Approved|InvestigationalTarget
DB00421SpironolactoneSmall Molecule52-01-7ApprovedTarget
DB09089TrimebutineSmall Molecule39133-31-8ApprovedTarget
DB09231BenidipineSmall Molecule105979-17-7Approved|InvestigationalTarget
DB09232CilnidipineSmall Molecule132203-70-4Approved|InvestigationalTarget
DB09236LacidipineSmall Molecule103890-78-4Approved|InvestigationalTarget
DB09238ManidipineSmall Molecule89226-50-6Approved|InvestigationalTarget
ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of CACNB2 mRNA"19114083
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CACNB2 mRNA"23196670
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of CACNB2 mRNA29067470
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA25607892
D000643Ammonium ChlorideAmmonium Chloride affects the expression of CACNB2 mRNA16483693
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA25607892
C006632arsenic trioxidearsenic trioxide results in increased expression of CACNB2 mRNA20458559
C015001arsenitearsenite results in increased methylation of CACNB2 promoter23974009
D001280AtrazineAtrazine results in decreased expression of CACNB2 mRNA25929836
C547126AZM551248AZM551248 results in decreased expression of CACNB2 mRNA22323515
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of CACNB2 mRNA22228805
D004958EstradiolEstradiol results in decreased expression of CACNB2 mRNA21185374
C006780bisphenol Abisphenol A affects the methylation of CACNB2 promoter27415467
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of CACNB2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of CACNB2 gene28505145
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA25607892
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of CACNB2 mRNA17484886
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of CACNB2 mRNA26272509
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CACNB2 gene20938992
D003010ClorgylineClorgyline results in increased expression of CACNB2 mRNA19691856
D016572CyclosporineCyclosporine results in decreased expression of CACNB2 mRNA20106945
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of CACNB2 mRNA23914054
C058705diethyl malatediethyl malate affects the expression of CACNB2 mRNA24814887
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA25607892
C074283estradiol 3-benzoateestradiol 3-benzoate results in increased methylation of CACNB2 promoter27415467
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of CACNB2 mRNA15212814
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CACNB2 gene20938992
D019833GenisteinGenistein results in increased expression of CACNB2 mRNA24967385
C002385linsidominelinsidomine results in increased oxidation of CACNB2 protein28086193
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CACNB2 gene20938992
D008731MethoxychlorMethoxychlor results in increased methylation of CACNB2 gene23303685
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of CACNB2 mRNA28001369
C517284monomethyl phthalatemonomethyl phthalate affects the expression of CACNB2 mRNA26924002
C523799MRK 003CACNB2 results in increased susceptibility to MRK 00319903844
D009151Mustard GasMustard Gas affects the expression of CACNB2 mRNA15651846
D009532NickelNickel results in decreased expression of CACNB2 mRNA25583101
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA25607892
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of CACNB2 mRNA26272509
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of CACNB2 mRNA19162173
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of CACNB2 mRNA26272509
D011192Potassium DichromatePotassium Dichromate results in decreased expression of CACNB2 mRNA23608068
C009277sodium arsenatesodium arsenate results in increased expression of CACNB2 mRNA21795629
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of CACNB2 mRNA20106945
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased methylation of CACNB2 gene26756918
D014241TrichloroethyleneTrichloroethylene results in increased methylation of CACNB2 gene27618143
D014415TunicamycinTunicamycin results in increased expression of CACNB2 mRNA17127020
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of CACNB2 gene25560391
D014750VincristineVincristine results in increased expression of CACNB2 mRNA23649840

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005245voltage-gated calcium channel activity-IDA1309651  
GO:0005262calcium channel activity-NAS9594024  
GO:0005515protein binding-IPI17525370  
GO:0008331high voltage-gated calcium channel activity-IBA21873635  
GO:0008331high voltage-gated calcium channel activitycontributes_toIDA1309651  
GO:0051015actin filament binding-ISS25533460  
GO:0086007voltage-gated calcium channel activity involved in cardiac muscle cell action potentialcontributes_toIMP17224476  
GO:0086056voltage-gated calcium channel activity involved in AV node cell action potentialcontributes_toIMP17224476  
GO ID GO Term Qualifier Evidence PubMed
GO:0007268chemical synaptic transmission-IBA21873635  
GO:0007528neuromuscular junction development-IBA21873635  
GO:0007528neuromuscular junction development-TAS8494331  
GO:0007601visual perception-IEA-  
GO:0051928positive regulation of calcium ion transport-IDA1309651  
GO:0070509calcium ion import-IDA1309651  
GO:0070588calcium ion transmembrane transport-IEA-  
GO:0072659protein localization to plasma membrane-ISS25533460  
GO:0086045membrane depolarization during AV node cell action potential-IMP17224476  
GO:0086091regulation of heart rate by cardiac conduction-IMP17224476  
GO:0098912membrane depolarization during atrial cardiac muscle cell action potential-IMP17224476  
GO:1901385regulation of voltage-gated calcium channel activity-IBA21873635  
GO:1901843positive regulation of high voltage-gated calcium channel activity-ISS25533460  
GO:1904879positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel-ISS25533460  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-NAS9594024  
GO:0005891voltage-gated calcium channel complex-IBA21873635  
GO:0005891voltage-gated calcium channel complex-IDA17224476  
GO:1990454L-type voltage-gated calcium channel complex-IDA1309651  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04260Cardiac muscle contraction
hsa05410Hypertrophic cardiomyopathy (HCM)
hsa05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)
hsa05414Dilated cardiomyopathy
Reactome ID Reactome Term Evidence
R-HSA-112308Presynaptic depolarization and calcium channel openingTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-1266738Developmental BiologyIEA
R-HSA-1430728MetabolismTAS
R-HSA-1430728MetabolismIEA
R-HSA-163685Integration of energy metabolismTAS
R-HSA-163685Integration of energy metabolismIEA
R-HSA-375165NCAM signaling for neurite out-growthIEA
R-HSA-397014Muscle contractionTAS
R-HSA-400042Adrenaline,noradrenaline inhibits insulin secretionIEA
R-HSA-419037NCAM1 interactionsIEA
R-HSA-422356Regulation of insulin secretionTAS
R-HSA-422356Regulation of insulin secretionIEA
R-HSA-422475Axon guidanceIEA
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576892Phase 0 - rapid depolarisationTAS
R-HSA-5576893Phase 2 - plateau phaseTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal